FDA panel push for whooping cough vaccines

Share this article:

A U.S. advisory panel yesterday urged the approval for two new vaccines designed to boost immunity against whooping cough.
The panel said the vaccines, GlaxoSmithKline's Boostrix and Sanofi-Aventis' Adacel, appear safe and effective for use as booster shots after whooping cough immunity has waned. The FDA usually follows the recommendations of its advisory panels.
GSK is seeking to market Boostrix for people age 10 to 18, while Sanofi-Aventis wants to sell Adacel to a larger group of people age 11 to 64, according to a Reuters report.
Boostrix and Adacel are the first products to combine a whooping cough vaccine with the routine tetanus and diptheria booster shot given to adolescents.
Concern about whooping cough, also known as pertussis, has grown recently as reports of deaths from the disease are on the rise in the U.S. and older people who carry the bacteria can easily infect young, unvaccinated children.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.